Regulatory T cells, CD4+CD25+FOXР3+CD127LOW, in patients with vulgar psoriasis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aims. To determine the role of regulatory cells (Treg) in patients with vulgar psoriasis (VP) and to provide evidence of its possible role in diagnosis, treatment, and measurement of therapeutic efficacy.

Material and methods. We studied 60 patients (35 women and 25 men) with VP, ages ranging from 18 to 55 years. Of these, 28 patients had VP in the progressive stage, 19 were stable, and 8 had resolution of the disease. Overall, 42 patients had VP for less than 20 years and 28 patients for 20 years and more. Patients were divided based on VP severity into the following three groups: mild (10 patients), moderate (22 patients), and severe (28 patients). In addition, the amount of Treg was examined before and after narrow-band ultraviolet-B (UVB) therapy in 12 patients with the progressive stage of VP. The healthy donors (HD) group consisted of 22 persons.

Results. A reduction in the number of Treg, CD4+CD25+Foxр3+CD127LOW, was observed in the peripheral blood of patients with VP (2.84% ± 1.00% for patients with VP and 4.02% ± 0.73% for HD), with an increase in their number with stage transition (2.59% ± 0.68% in the progressive stage, 2.82% ± 1.55% in stable, and 3.68% ± 1.62% in the resolution period). An inverse correlation was determined not only between the number of Treg and the degree of VP severity (r = -0.39) but also with disease duration (r = -0.46). In addition, NB-UVB phototherapy was noted to promote an increase in the amount of Treg.

Full Text

Restricted Access

About the authors

O. Yu. Olisova

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: lakmus1991@gmail.com
ORCID iD: 0000-0003-2482-1754

Department of Dermatology and Venereology

Russian Federation, 119991, Moscow

S. N. Bykovskaia

Pirogov Russian National Research Medical University

Email: lakmus1991@gmail.com
ORCID iD: 0000-0001-9958-7750

Department of Cell Technologies and Tissue Regeneration 

Russian Federation, 117997, Moscow,

V. V. Gudova

I.M. Sechenov First Moscow State Medical University

Email: lakmus1991@gmail.com
ORCID iD: 0000-0003-1141-7437

postgraduate student of Department of Dermatology and Venereology

Russian Federation, 119991, Moscow

References

  1. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu. Rev. Immunol. 2014; 32(1):227-55.
  2. Baliwag J., Barnes D.H., Johnston A. Cytokines in psoriasis. Cytokine. 2015; 73(2):342-50.
  3. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002; 109(1):131-40.
  4. de Kleer I.M., Wedderburn L.R., Taams L.S., Patel A., Varsani H., Klein M., et al. CD4+ CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 2004; 172(10):6435-43.
  5. Crispin J. C., Alcocer-Varela J., de Pablo P., Martinez A., Richaud-Patin Y., Alarcon-Segovia D. Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. Lupus. 2003; 12(5):386-93.
  6. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.L., et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008; 123(1):79-89.
  7. Lyssuk E.Y., Torgashina A.V., Soloviev S.K., Nassonov E.L., Bykovskaia S.N. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 2007; 601: 113-9.
  8. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human auto- immune diseases. Nat. Rev. Immunol. 2010; 10(12):849-59.
  9. Afzali B., Edozie F.C., Fazekasova H., Edozie F.C., Fazekasova H., Scotta C., et al. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin. J. Am. Soc. Nephrol. 2013; 8(8):1396-405.
  10. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 2003; 4(4):330-6.
  11. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 2007; 8(3):277-84.
  12. Gambineri E., Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T cell homeostasis. Curr. Opin. Rheumatol. 2007; 15(4):430-5.
  13. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J. Exp. Med. 2006; 203(7):1701-11.
  14. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006; 203(7):1693-700.
  15. Hartigan-O’Connor D.J., Poon C., Sinclair E., McCune J.M. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J. Immunol. Methods. 2007; 319 (1-2):41-52.
  16. Yadav M., Stephan S., Bluestone J.A. Peripherally induced tregs – role in immune homeostasis and autoimmunity. Front. Immunol. 2013; 4:232.
  17. Bach J.F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 2001; 19:131-61.
  18. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting edge: CD4+ CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalo-myelitis. J. Immunol. 2002; 169(9):4712-6.
  19. Wu A.J., Hua H., Munson S.H., McDevitt H.O. Tumor necrosis factor-alpha regulation of CD4+ CD25+ T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA. 2002; 99(19):12287-92.
  20. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 2002; 196(3):389-99.
  21. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun. Rev. 2011; 10(12):744-55.
  22. Khairutdinov V.R., Michailichenko A.F., Mukhina M.A., Samtsov А.V., Imyanitov E.N., Ivanov A.M. The role of T-regulatory cells in the pathogenesis of psoriasis. Herald of Venerology and Dermatol. Russian Journal (Vestnik Dermatologii i Venerologii). 2011; (5): 78-85.
  23. Richetta A.G., Mattozzi C., Salvi M., Giancristoforo S., D’epiro S., Milana B., et al. CD4+ CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement. Eur. J. Dermatol. 2011; 21(3):344-8.
  24. Kagen M.H., McCormick T.S., Cooper K.D. Regulatory T cells in psoriasis. Ernst Schering Res. Found Workshop. 2006; (56):193-209.
  25. Keijsers R.R., van der Velden H.M., van Erp P.E., de Boer-van Huizen R.T., Joosten I., Koenen H.J., van de Kerkhof P.C. Balance of Treg vs T-helper cells in the transition from symptomless to lesional psoriatic skin. Br. J. Dermatol. 2013; 168(6): 1294-302.
  26. Quaglino P., Bergallo M., Ponti R., Barberio E., Cicchelli S., Buffa E., et al. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology. 2011; 223(1):57-67.
  27. Furuhashi T., Saito C., Torii K., Nishida E., Yamazaki S., Morita A. Photo(chemo) therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One. 2013; 8(1):e54895.
  28. Kubo R., Muramatsu S., Sagawa Y., Saito C., Kasuya S., Nishioka A., et al. Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis. J. Dermatol. Sci. 2017; 86(1):46-53.
  29. Kotb I.S., Lewis B.J., Barker R.N., Ormerod A.D. Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis. Br. J. Dermatol. 2018; 179(1):127-35.
  30. Mattozzi C., Paolino G., Salvi M., Macaluso L., Luci C., Morrone S., et al. Peripheral blood regulatory T cell measurements correlate with serum vitamin D level in patients with psoriasis. Eur. Rev. Med. Pharmacol. Sci. 2016; 20(9):1675-9.
  31. Soler D.C., Sugiyama H., Young A.B., Massari J.V., McCormick T.S., Cooper K.D., et al. Psoriasis patients exhibit impairment of the high potency CCR5+ T regulatory cell subset. Clin. Immunol. 2013; 149(1):111-8.
  32. Eliseeva D.D., Zavalishin I.A., Bykovskaya S.N., Fedorova T.N., Karandashov E.N., Trunova O.A. Regulatory T-cells CD4+CD25+Foxр3+ in patients with remitting multiple sclerosis. Annals of Clinical and Experimental Neurology. Russian Journal (Annaly klinicheskoi i eksperimentalnoi nevrologii). 2011; 5(2):9-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies